Illinois secured a $45 million settlement with CVS Caremark over pharmacy benefit management transparency issues.

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

Gifting allows recipients to access the article for free. Illinois will recover $45 million in CVS Caremark pharmacy rebates after the pharmacy benefit manager settled with the state attorney ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Diversified healthcare company CVS Health (NYSE:CVS) announced better-than-expected revenue in Q1 CY2025, with sales up 7% ...

CVS Health Corporation CVS and The Cigna Group CI shares trading lower Tuesday. President Donald Trump on Monday signed an ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

CVS Caremark announced a partnership with Novo Nordisk (NYSE:NVO) to expand access to Wegovy, a GLP-1 drug for obesity, at a more affordable price. Starting July 1, 2025, Wegovy will become the ...